Berichte in der Schilddrüsenforschung

The Dual Role of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists in Prostate Cancer: From Diabetes to Oncology

Abstract

Abdulrahman David

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) are widely used in the management of type 2 diabetes due to their glucose-lowering effects and favorable safety profile. However, emerging evidence suggests that GLP-1 RAs may also have a dual role in prostate cancer, with both beneficial and potentially harmful effects. This article provides an overview of the current understanding of the dual role of GLP-1 RAs in prostate cancer, highlighting their potential as a therapeutic target in oncology.